1. [Acquired thrombotic thrombocytopenic purpura during durvalumab monotherapy for non-small cell lung cancer].
- Author
-
Shimada S, Kuroiwa K, Narita H, Okamura R, Uesugi Y, Sasaki Y, Watanuki M, Arai N, Kawaguchi Y, Fujiwara S, Yanagisawa K, and Hattori N
- Subjects
- Female, Humans, Aged, Antibodies, Monoclonal adverse effects, Plasma Exchange adverse effects, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung etiology, Purpura, Thrombotic Thrombocytopenic chemically induced, Purpura, Thrombotic Thrombocytopenic diagnosis, Purpura, Thrombotic Thrombocytopenic therapy, Lung Neoplasms drug therapy, Lung Neoplasms etiology
- Abstract
Immune checkpoint inhibitor (ICI)-induced thrombocytopenias are rare immune-related adverse events (irAE), but ICI-related thrombotic thrombocytopenic purpura (TTP) is extremely rare. A 79-year-old woman with non-small cell lung cancer received maintenance therapy with the anti-human PD-L1 monoclonal antibody durvalumab. Four weeks after the last infusion, she developed overt TTP. Remission was achieved by plasma exchange and prednisolone, and the patient has now been recurrence-free for over 12 months. To our knowledge, this is the first report of TTP occurring as an irAE of durvalumab.
- Published
- 2024
- Full Text
- View/download PDF